Meridian Life Science, Inc.
5171 Wilfong Road
Memphis
Tennessee
38134
United States
Tel: 901-382-8716
Website: http://www.meridianlifescience.com/
Email: info@meridianlifescience.com
About Meridian Life Science, Inc.
Meridian Bioscience is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and biopharmaceutical enabling technologies that help deliver answers. Our products provide accuracy, simplicity and speed for the early diagnosis and treatment of common medical conditions, such as C. difficile, H. pylori., foodborne diseases. and respiratory infections.
For more than 30 years, Meridian Bioscience, Inc., has established a proven track record of profitable growth and product launches designed to enhance patient well being while reducing the total outcome costs of healthcare. Meridian diagnostic products are used outside of the human body and require little or no special equipment.
We maintain market leadership by responding to emerging diseases and changing medical needs. Since 1991, Meridian has developed and introduced more than 56 innovative products. Meridian also grows through acquisition, licensing, or supply agreements that have added almost 100 new products to our catalog.
Meridian has strong market positions in the areas of gastrointestinal infections, serology, parasitology and fungal disease diagnosis. We actively market our products to hospitals, reference laboratories, research centers, physician offices and diagnostics manufacturers in more than 60 countries around the world.
Our shares are traded on the NASDAQ National Market, symbol VIVO.
192 articles about Meridian Life Science, Inc.
-
Meridian Bioscience Receives FDA Clearance For New Molecular Whooping Cough Test Claims
11/19/2015
-
Meridian Bioscience Announces Investment In Oasis Diagnostics
11/13/2015
-
Meridian Bioscience Reports Fourth Quarter And Full-Year Operating Results, Declares Regular Cash Dividend, And Reaffirms Fiscal 2016 Guidance
11/5/2015
-
Meridian Bioscience Provides Net Revenues And Earnings Guidance For Fiscal 2016
9/9/2015
-
Meridian Bioscience Elects Catherine Sazdanoff And John Mcilwraith To The Board Of Directors
8/17/2015
-
Meridian Bioscience Reports Third Quarter And Nine Months Operating Results, Declares Regular Cash Dividend, And Reaffirms Fiscal 2015 Guidance
7/23/2015
-
Meridian Bioscience Snags FDA OK for New Molecular Amplification Test: illumigene HSV 1&2
7/20/2015
-
Meridian Bioscience, Inc. Launches Para-Pak SVT (Single Vial Transport)
6/4/2015
-
Meridian Bioscience, Inc. Europe Launches New Molecular Tests For The Detection Of Herpes Simplex Virus Type 1 And Type 2
5/21/2015
-
Meridian Bioscience, Inc. Reports Second Quarter 2015 Operating Results, Declares Regular Cash Dividend, And Reaffirms Fiscal 2015 Guidance
4/23/2015
-
Meridian Bioscience, Inc. Launches New TRU Brand Test For The Detection Of Streptococcus Pneumoniae In Urine And CSF
2/26/2015
-
Meridian Bioscience, Inc. Bioscience Receives CE Marking For Two New Molecular Amplification Tests: Illumigene® Chlamydia And Illumigene Gonorrhea
2/26/2015
-
Meridian Bioscience, Inc. Reports First Quarter 2015 Operating Results, Declares Regular Cash Dividend, And Reaffirms Fiscal 2015 Guidance
1/22/2015
-
Meridian Bioscience, Inc. Opens A New Office In Beijing, China
1/9/2015
-
Meridian Bioscience, Inc. Reports Fourth Quarter And Full-Year Operating Results, Declares Regular Cash Dividend, And Reaffirms Fiscal 2015 Guidance
11/6/2014
-
Meridian Bioscience, Inc. Signs Agreement With Premier, Inc. To Offer Its Hospitals Molecular Diagnostic Tests And Instruments For C. Difficile, Group B Streptococcus, Group A Streptococcus, Bordetella Pertussis, And Mycoplasma Pneumoniae
9/3/2014
-
Meridian Bioscience, Inc. Provides Net Revenues And Earnings Guidance For Fiscal 2015 And Reaffirms Fiscal 2014 Guidance
9/2/2014
-
Meridian Bioscience, Inc. And The University Of Tennessee Research Foundation Enter Into A License Agreement For Electrokinetic Sensor Technology
8/6/2014
-
Meridian Bioscience, Inc. Reports Third Quarter And Nine Months Operating Results, Declares Regular Cash Dividend, And Reaffirms Fiscal 2014 Guidance
7/24/2014
-
Meridian Bioscience, Inc. Receives Canadian Licenses For Illumigene® Mycoplasma And Illumigene® Pertussis
5/28/2014